White kids who have a certain genetic change (R46L) in the PCSK9 gene tend to have lower 'bad' cholesterol levels from a young age—this finding is from the abstract summary - full study details were not available
Evidence from Studies
Supporting (1)
Community contributions welcome
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether inducing PCSK9 inhibition (e.g., via monoclonal antibodies or gene editing) directly causes LDL cholesterol reduction in children with and without the mutation.
A double-blind, placebo-controlled RCT enrolling 300 white children aged 5–10 years, half with the PCSK9 R46L mutation and half without, randomized to receive either PCSK9 inhibitor (e.g., evolocumab 140 mg subcutaneously every 2 weeks) or placebo for 12 months, measuring primary outcome of change in LDL cholesterol from baseline via standardized assays.
The overall strength and consistency of the association between PCSK9 R46L mutation and childhood LDL cholesterol across all available population studies.
A systematic review and meta-analysis of all prospective cohort and cross-sectional studies reporting LDL cholesterol levels in children aged 4–12 years with and without the PCSK9 R46L variant, stratified by race, using standardized mean differences as effect size, with risk of bias and heterogeneity assessment.
Whether the PCSK9 R46L mutation is linked to lower LDL cholesterol over time from childhood into adulthood in a real-world population.
A multi-ethnic prospective cohort study following 2,000 children from age 4 to 30 years, genotyped for PCSK9 R46L, with annual LDL cholesterol measurements, adjusting for diet, BMI, and medication use, to assess lifelong lipid trajectories.